These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 18337766)

  • 61. Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways.
    García-Echeverría C
    Purinergic Signal; 2009 Mar; 5(1):117-25. PubMed ID: 18523868
    [TBL] [Abstract][Full Text] [Related]  

  • 62. New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update.
    Montaño A; Forero-Castro M; Marchena-Mendoza D; Benito R; Hernández-Rivas JM
    Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29642462
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Signaling networks in MS: a systems-based approach to developing new pharmacological therapies.
    Kotelnikova E; Bernardo-Faura M; Silberberg G; Kiani NA; Messinis D; Melas IN; Artigas L; Schwartz E; Mazo I; Masso M; Alexopoulos LG; Mas JM; Olsson T; Tegner J; Martin R; Zamora A; Paul F; Saez-Rodriguez J; Villoslada P
    Mult Scler; 2015 Feb; 21(2):138-46. PubMed ID: 25112814
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response.
    Martelli AM; Paganelli F; Fazio A; Bazzichetto C; Conciatori F; McCubrey JA
    Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31064074
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Retraction: Leptin Induces Cyclin D1 Expression and Proliferation of Human Nucleus Pulposus Cells via JAK/STAT, PI3K/Akt and MEK/ERK Pathways.
    PLOS ONE Editors
    PLoS One; 2023; 18(3):e0282978. PubMed ID: 36989244
    [No Abstract]   [Full Text] [Related]  

  • 66. Targeted therapy in leukemia.
    Downing JR
    Mod Pathol; 2008 May; 21 Suppl 2():S2-7. PubMed ID: 18437169
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe.
    Epstein RJ
    Front Oncol; 2013 Dec; 3():304. PubMed ID: 24377088
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Targeting Dysregulated Lipid Metabolism in Cancer with Pharmacological Inhibitors.
    Gupta A; Das D; Taneja R
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610991
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Erratum: Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells.
    Du W; Pang C; Xue Y; Zhang Q; Wei X
    Oncol Lett; 2021 May; 21(5):375. PubMed ID: 33777199
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Combination Therapy: JAK PI3K/mTOR. A Novel Approach for Cancer Treatment.
    Abdel-Magid AF
    ACS Med Chem Lett; 2013 May; 4(5):429-30. PubMed ID: 24900688
    [No Abstract]   [Full Text] [Related]  

  • 71. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.
    Steelman LS; Abrams SL; Whelan J; Bertrand FE; Ludwig DE; Bäsecke J; Libra M; Stivala F; Milella M; Tafuri A; Lunghi P; Bonati A; Martelli AM; McCubrey JA
    Leukemia; 2008 Apr; 22(4):686-707. PubMed ID: 18337767
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway.
    Zheng Y; Qin H; Frank SJ; Deng L; Litchfield DW; Tefferi A; Pardanani A; Lin FT; Li J; Sha B; Benveniste EN
    Blood; 2011 Jul; 118(1):156-66. PubMed ID: 21527517
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasms.
    Kaehler M; von Bubnoff N; Cascorbi I; Gorantla SP
    Front Pharmacol; 2024; 15():1422565. PubMed ID: 39104388
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Biological roles of SLC16A1-AS1 lncRNA and its clinical impacts in tumors.
    Liao B; Wang J; Yuan Y; Luo H; Ouyang X
    Cancer Cell Int; 2024 Mar; 24(1):122. PubMed ID: 38555465
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer.
    Zafeiropoulou K; Kalampounias G; Alexis S; Anastasopoulos D; Symeonidis A; Katsoris P
    PLoS One; 2024; 19(2):e0289904. PubMed ID: 38412186
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies.
    Zarrabi A; Perrin D; Kavoosi M; Sommer M; Sezen S; Mehrbod P; Bhushan B; Machaj F; Rosik J; Kawalec P; Afifi S; Bolandi SM; Koleini P; Taheri M; Madrakian T; Łos MJ; Lindsey B; Cakir N; Zarepour A; Hushmandi K; Fallah A; Koc B; Khosravi A; Ahmadi M; Logue S; Orive G; Pecic S; Gordon JW; Ghavami S
    Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958442
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Advancement of regulating cellular signaling pathways in NSCLC target therapy via nanodrug.
    Li W; Li M; Huang Q; He X; Shen C; Hou X; Xue F; Deng Z; Luo Y
    Front Chem; 2023; 11():1251986. PubMed ID: 37744063
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Question of Survival or Death: What Is the Role of Autophagy in Acute Myeloid Leukemia (AML)?
    Haghi A; Mohammadi Kian M; Salemi M; Eghdami MR; Nikbakht M
    Int J Hematol Oncol Stem Cell Res; 2022 Oct; 16(4):250-263. PubMed ID: 36883106
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.
    Kaehler M; Cascorbi I
    Handb Exp Pharmacol; 2023; 280():65-83. PubMed ID: 36882601
    [TBL] [Abstract][Full Text] [Related]  

  • 80. N-myc downstream regulated gene 1 inhibition of tumor progression in Caco2 cells.
    He YX; Shen H; Ji YZ; Hua HR; Zhu Y; Zeng XF; Wang F; Wang KX
    World J Gastrointest Oncol; 2022 Dec; 14(12):2313-2328. PubMed ID: 36568939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.